AAPL315.34-0.88 (-0.28%) ▼|ABBV250.91+2.13 (+0.86%) ▲|ABT104.61-0.64 (-0.61%) ▼|ACN175.94+0.10 (+0.06%) ▲|ADBE250.87-4.00 (-1.57%) ▼|AMAT456.67-12.19 (-2.60%) ▼|AMD509.74-11.36 (-2.18%) ▼|AMGN390.18-1.09 (-0.28%) ▼|AMT174.98-0.60 (-0.34%) ▼|AMZN251.14-1.26 (-0.50%) ▼|AVGO359.25-5.13 (-1.41%) ▼|AXP321.15-0.65 (-0.20%) ▼|BA207.29+0.81 (+0.39%) ▲|BAC62.61-0.08 (-0.13%) ▼|BKNG173.65+0.22 (+0.13%) ▲|BLK1,067.32-5.20 (-0.48%) ▼|BMY64.39-0.02 (-0.03%) ▼|BNY162.60+0.03 (+0.02%) ▲|BRK-B507.32+0.56 (+0.11%) ▲|C138.00+0.19 (+0.14%) ▲|CAT809.00-7.05 (-0.86%) ▼|CL88.66+0.65 (+0.73%) ▲|CMCSA24.74+0.15 (+0.61%) ▲|COF209.00-1.95 (-0.92%) ▼|COP137.89+1.28 (+0.94%) ▲|COST910.45+7.85 (+0.87%) ▲|CRM244.22+0.02 (+0.01%) ▲|CSCO109.31-0.12 (-0.11%) ▼|CVS96.74+1.36 (+1.42%) ▲|CVX215.32+1.50 (+0.70%) ▲|DE676.67-0.62 (-0.09%) ▼|DHR200.69-4.30 (-2.10%) ▼|DIS104.09-0.09 (-0.08%) ▼|DUK120.79+0.35 (+0.29%) ▲|EMR148.07-2.33 (-1.55%) ▼|FDX308.33-0.90 (-0.29%) ▼|GD353.93+1.25 (+0.35%) ▲|GE323.99-1.45 (-0.45%) ▼|GEV937.18-13.43 (-1.41%) ▼|GILD145.60-0.06 (-0.04%) ▼|GM84.25+0.47 (+0.56%) ▲|GOOG327.17-1.21 (-0.37%) ▼|GOOGL329.11-1.54 (-0.47%) ▼|GS1,020.92-8.44 (-0.82%) ▼|HD306.26-4.23 (-1.36%) ▼|HON202.20-2.74 (-1.33%) ▼|IBM236.52-3.45 (-1.44%) ▼|INTC101.21-5.03 (-4.73%) ▼|INTU311.27-2.67 (-0.85%) ▼|ISRG349.01-4.23 (-1.20%) ▼|JNJ269.88+2.69 (+1.00%) ▲|JPM353.34-1.35 (-0.38%) ▼|KO88.65+1.07 (+1.22%) ▲|LIN466.67+0.02 (+0.00%) ▲|LLY1,130.15+5.89 (+0.52%) ▲|LMT526.16+1.67 (+0.32%) ▲|LOW196.14-2.47 (-1.24%) ▼|LRCX303.62-12.22 (-3.87%) ▼|MA564.85-2.77 (-0.49%) ▼|MCD254.89+1.35 (+0.53%) ▲|MDLZ62.39-0.04 (-0.06%) ▼|MDT91.36-0.55 (-0.60%) ▼|META653.24-0.45 (-0.07%) ▼|MMM162.71-1.71 (-1.04%) ▼|MO68.81+0.90 (+1.32%) ▲|MRK147.25-0.34 (-0.23%) ▼|MS214.48-0.87 (-0.40%) ▼|MSFT488.14-3.51 (-0.71%) ▼|MU987.89-39.88 (-3.88%) ▼|NEE83.02+0.35 (+0.42%) ▲|NFLX75.10-0.93 (-1.22%) ▼|NKE36.97-0.39 (-1.03%) ▼|NOW131.90+0.79 (+0.60%) ▲|NVDA219.19-4.48 (-2.00%) ▼|ORCL157.72-4.00 (-2.48%) ▼|PEP136.87+0.18 (+0.13%) ▲|PFE27.68-0.11 (-0.38%) ▼|PG143.04+0.37 (+0.26%) ▲|PLTR165.81-3.72 (-2.19%) ▼|PM189.72+4.03 (+2.17%) ▲|QCOM171.81-4.59 (-2.60%) ▼|RTX197.28-0.30 (-0.15%) ▼|SBUX99.90-0.14 (-0.14%) ▼|SCHW107.02+0.48 (+0.45%) ▲|SO88.63+0.28 (+0.32%) ▲|SPG206.05+1.42 (+0.69%) ▲|T25.65+0.49 (+1.95%) ▲|TMO599.60-6.57 (-1.08%) ▼|TMUS178.45+1.11 (+0.63%) ▲|TSLA361.49-6.33 (-1.72%) ▼|TXN257.18-4.41 (-1.69%) ▼|UBER69.68-1.43 (-2.00%) ▼|UNH398.24+5.17 (+1.31%) ▲|UNP287.53+2.74 (+0.96%) ▲|UPS99.38+0.16 (+0.16%) ▲|USB62.24+0.11 (+0.17%) ▲|V366.64-0.94 (-0.26%) ▼|VZ50.51+0.75 (+1.51%) ▲|WFC89.75+0.07 (+0.07%) ▲|WMT107.00+1.17 (+1.10%) ▲|XOM164.83+0.57 (+0.34%) ▲|AAPL315.34-0.88 (-0.28%) ▼|ABBV250.91+2.13 (+0.86%) ▲|ABT104.61-0.64 (-0.61%) ▼|ACN175.94+0.10 (+0.06%) ▲|ADBE250.87-4.00 (-1.57%) ▼|AMAT456.67-12.19 (-2.60%) ▼|AMD509.74-11.36 (-2.18%) ▼|AMGN390.18-1.09 (-0.28%) ▼|AMT174.98-0.60 (-0.34%) ▼|AMZN251.14-1.26 (-0.50%) ▼|AVGO359.25-5.13 (-1.41%) ▼|AXP321.15-0.65 (-0.20%) ▼|BA207.29+0.81 (+0.39%) ▲|BAC62.61-0.08 (-0.13%) ▼|BKNG173.65+0.22 (+0.13%) ▲|BLK1,067.32-5.20 (-0.48%) ▼|BMY64.39-0.02 (-0.03%) ▼|BNY162.60+0.03 (+0.02%) ▲|BRK-B507.32+0.56 (+0.11%) ▲|C138.00+0.19 (+0.14%) ▲|CAT809.00-7.05 (-0.86%) ▼|CL88.66+0.65 (+0.73%) ▲|CMCSA24.74+0.15 (+0.61%) ▲|COF209.00-1.95 (-0.92%) ▼|COP137.89+1.28 (+0.94%) ▲|COST910.45+7.85 (+0.87%) ▲|CRM244.22+0.02 (+0.01%) ▲|CSCO109.31-0.12 (-0.11%) ▼|CVS96.74+1.36 (+1.42%) ▲|CVX215.32+1.50 (+0.70%) ▲|DE676.67-0.62 (-0.09%) ▼|DHR200.69-4.30 (-2.10%) ▼|DIS104.09-0.09 (-0.08%) ▼|DUK120.79+0.35 (+0.29%) ▲|EMR148.07-2.33 (-1.55%) ▼|FDX308.33-0.90 (-0.29%) ▼|GD353.93+1.25 (+0.35%) ▲|GE323.99-1.45 (-0.45%) ▼|GEV937.18-13.43 (-1.41%) ▼|GILD145.60-0.06 (-0.04%) ▼|GM84.25+0.47 (+0.56%) ▲|GOOG327.17-1.21 (-0.37%) ▼|GOOGL329.11-1.54 (-0.47%) ▼|GS1,020.92-8.44 (-0.82%) ▼|HD306.26-4.23 (-1.36%) ▼|HON202.20-2.74 (-1.33%) ▼|IBM236.52-3.45 (-1.44%) ▼|INTC101.21-5.03 (-4.73%) ▼|INTU311.27-2.67 (-0.85%) ▼|ISRG349.01-4.23 (-1.20%) ▼|JNJ269.88+2.69 (+1.00%) ▲|JPM353.34-1.35 (-0.38%) ▼|KO88.65+1.07 (+1.22%) ▲|LIN466.67+0.02 (+0.00%) ▲|LLY1,130.15+5.89 (+0.52%) ▲|LMT526.16+1.67 (+0.32%) ▲|LOW196.14-2.47 (-1.24%) ▼|LRCX303.62-12.22 (-3.87%) ▼|MA564.85-2.77 (-0.49%) ▼|MCD254.89+1.35 (+0.53%) ▲|MDLZ62.39-0.04 (-0.06%) ▼|MDT91.36-0.55 (-0.60%) ▼|META653.24-0.45 (-0.07%) ▼|MMM162.71-1.71 (-1.04%) ▼|MO68.81+0.90 (+1.32%) ▲|MRK147.25-0.34 (-0.23%) ▼|MS214.48-0.87 (-0.40%) ▼|MSFT488.14-3.51 (-0.71%) ▼|MU987.89-39.88 (-3.88%) ▼|NEE83.02+0.35 (+0.42%) ▲|NFLX75.10-0.93 (-1.22%) ▼|NKE36.97-0.39 (-1.03%) ▼|NOW131.90+0.79 (+0.60%) ▲|NVDA219.19-4.48 (-2.00%) ▼|ORCL157.72-4.00 (-2.48%) ▼|PEP136.87+0.18 (+0.13%) ▲|PFE27.68-0.11 (-0.38%) ▼|PG143.04+0.37 (+0.26%) ▲|PLTR165.81-3.72 (-2.19%) ▼|PM189.72+4.03 (+2.17%) ▲|QCOM171.81-4.59 (-2.60%) ▼|RTX197.28-0.30 (-0.15%) ▼|SBUX99.90-0.14 (-0.14%) ▼|SCHW107.02+0.48 (+0.45%) ▲|SO88.63+0.28 (+0.32%) ▲|SPG206.05+1.42 (+0.69%) ▲|T25.65+0.49 (+1.95%) ▲|TMO599.60-6.57 (-1.08%) ▼|TMUS178.45+1.11 (+0.63%) ▲|TSLA361.49-6.33 (-1.72%) ▼|TXN257.18-4.41 (-1.69%) ▼|UBER69.68-1.43 (-2.00%) ▼|UNH398.24+5.17 (+1.31%) ▲|UNP287.53+2.74 (+0.96%) ▲|UPS99.38+0.16 (+0.16%) ▲|USB62.24+0.11 (+0.17%) ▲|V366.64-0.94 (-0.26%) ▼|VZ50.51+0.75 (+1.51%) ▲|WFC89.75+0.07 (+0.07%) ▲|WMT107.00+1.17 (+1.10%) ▲|XOM164.83+0.57 (+0.34%) ▲|
22.8 C
New York
Thursday, September 10, 2026

Tag: stages

newssourceFORcompanyinformationcontent1releasesmarket

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscular dystrophy (DMD) patients, irrespective of age, in both clinical and commercial settings. In the commercial setting, non-ambulatory patients should no longer receive Elevidys. In the clinical trial setting, enrolment and dosing of non-ambulatory patients will be immediately paused until additional risk mitigation measures (e.g. immune modulatory treatment) are implemented in the study protocol. Health authorities, investigators and physicians are being informed so that patient care can be quickly adjusted.

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx1.

Yesoul R1M PLUS Home Rowing Machine: A Full-Body Fitness Solution Designed for Men’s Health and Everyday Life

HONG KONG, June 14, 2025 /PRNewswire/ -- Coinciding with Men's Health Month, Yesoul promotes accessible home fitness tailored for today's busy men—from young professionals to...

CenterPoint Energy reaches settlement agreement on landmark Systemwide Resiliency Plan to strengthen Houston electric system against extreme weather threats and future hazards

Largest single resiliency investment in CenterPoint history will build on Greater Houston Resiliency Initiative and help address impacts of wide range of extreme weather and...

Curaleaf Reports on Voting Results from the 2025 Annual General Meeting of Shareholders

STAMFORD, Conn., June 13, 2025 /CNW/ -- The annual general meeting of shareholders of Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the...

Abbott Declares 406th Consecutive Quarterly Dividend

ABBOTT PARK, Ill., June 13, 2025 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 59...

Nimanode Presale Skyrockets Past 15% Softcap Target, Set to Give Early Participants First Mover Edge

LEEDS, United Kingdom, June 13, 2025 (GLOBE NEWSWIRE) -- The highly anticipated Nimanode (NMA) Presale has so far surpassed expectations, rapidly filling 15% of its softcap which has fuelled intense investor FOMO.

Streamlining Retirement Investments—A Strategic Approach for Optimized Returns

**Structured Portfolio Management in Retirement: A Disciplined Approach** As an experienced investor managing a portfolio of 10 different funds within your IRA, the decision to...

Taiwan Goes All-In for BIO in Boston: 2025’s Pavilion Promotes Biotech Innovation, Tech Power, and Global Partnerships

BOSTON, June 11, 2025 /PRNewswire/ -- Taiwan's delegation, led by BPIPO (Biotechnology and Pharmaceutical Industries Promotion Office), organized by the Ministry of Economic Affairs, and...

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

HAMPTON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab in chronic spontaneous urticaria (CSU), an immune-related condition driven by mast cell activation. Barzolvolimab specifically targets mast cells by binding the receptor tyrosine kinase KIT with high specificity and potently inhibiting its activity, which is required for mast cell function and survival.

4 Emerging Graft versus Host Disease Therapies That Could Change the Treatment Landscape | DelveInsight

Key companies, such as CSL Behring, Equillium, Biocon, and medac, are advancing their assets through late-stage graft versus host disease clinical trials, driving innovation...

ERRATUM – Innergex Announces the Repayment at Maturity of its 4.75% Convertible Unsecured Subordinated Debentures due June 30, 2025

LONGUEUIL, QC, June 12, 2025 /CNW/ - Innergex Renewable Energy Inc. (TSX: INE) ("Innergex" or the "Corporation") is pleased to announced its intention to...

Bay Area Lyme Foundation Announces National Winner of the 2025 Emerging Leader Award to Develop a Much-Needed Rapid, Low-Cost, Easy-to-Use Lyme Disease Test

Winner Chao Wang of Arizona State University will receive $150,000 to evaluate a unique diagnostic that uses gold nanoparticles and has been proven in other infectious diseases 
Winner Chao Wang of Arizona State University will receive $150,000 to evaluate a unique diagnostic that uses gold nanoparticles and has been proven in other infectious diseases

Yoomi™ Babytech Launches Patented Technology to Revolutionize Baby Bottle-Feeding and Transform Breastfeeding Recovery

Featuring the world's fastest self-warming bottles and a breakthrough in skin revival science for nipple care for breastfeeding moms, Yoomi™sets a new standard, Saving...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsStages

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers